AISA can control the inflammatory facet of SASP.

Senescent cells have been suspected, because of their secretory phenotype (SASP or Senescence Associated Secretory Profile), to contribute to the extension of the chronic inflammatory condition leading to unhealthy aging processes. AISA (Anti-Inflammatory Senescence Actives) monoterpens have been characterized as possessing anti-inflammatory capacities in young cells submitted to pro-inflammatory cytokine stimulation. They have also been demonstrated to have the ability to act on senescent cells, reversing their characteristic pro-inflammatory phenotype. This is due to the fact that AISA act on the cytoskeleton scaffold of cells where actin polymerization induces the expression of adhesion molecules, fueling the infernal inflammatory loop. In comparison to other isoprenoid actives in degenerative diseases, the AISA monoterpene adds a mood-modulating capacity inducing the vagus nerve tone and its potent anti-inflammatory role.